Equities

Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Actions
  • Price (USD)14.25
  • Today's Change0.16 / 1.14%
  • Shares traded112.58k
  • 1 Year change3.19%
  • Beta1.1180
Data delayed at least 15 minutes, as of Jan 21 2020 20:20 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

  • Revenue in USD (TTM)0.00
  • Net income in USD-69.83m
  • Incorporated2012
  • Employees24.00
  • Location
    Eiger BioPharmaceuticals Inc2155 Park BlvdPALO ALTO 94306-1543United StatesUSA
  • Phone+1 (650) 279-9845
  • Fax+1 (650) 618-1621
  • Websitehttp://www.eigerbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inovio Pharmaceuticals Inc6.34m-114.66m329.03m281.00--9.67--51.94-1.18-1.180.06490.34020.0434--3.5122,544.70-78.96-39.71-95.28-49.23-----1,821.08-203.75---19.610.6599---27.8017.75-9.93--63.78--
Kalvista Pharmaceuticals Inc14.11m-25.72m331.00m45.00--3.38--23.47-1.48-1.480.80925.480.1153--1.50313,444.40-21.03---24.13-------182.37------0.00--92.13---31.71------
Galera Therapeutics Inc0.00-52.03m332.92m-----------2.12-2.120.001.11------0.00-------------------83.110.6064-------5.16------
Tcr2 Therapeutics Inc0.00-96.09m338.40m71.00--1.97-----3.98-3.980.007.150.00----0.00-27.03---28.07--------------0.00-------314.08------
CytomX Therapeutics Inc60.68m-99.02m338.94m137.00--4.13--5.59-2.19-2.191.341.810.1419--1,926.38442,927.00-23.15-25.21-28.58-29.96-----163.17-174.88----0.00---16.92131.86-22.97--38.92--
Unity Biotechnology Inc0.00-86.07m339.51m103.00--2.84-----2.03-2.030.002.600.00----0.00-51.17---55.46--------------0.00---100.00---71.08------
Satsuma Pharmaceuticals Inc0.00-19.71m340.22m16.00--2.88-----1.19-1.190.006.80------0.00--------------------0.0411-------42.03------
Osmotica Pharmaceuticals PLC245.82m-350.08m344.28m466.00--2.16--1.40-9.15-9.155.432.720.36434.734.61527,503.60-51.88---60.60--49.14---142.42--1.78-0.72820.6544--7.31---165.90------
Eiger Biopharmaceuticals Inc0.00-69.83m345.14m24.00--4.82-----3.33-3.330.002.930.00----0.00-74.54-60.27-89.48-69.90-----------51.420.2965-------23.42--10.29--
Stemline Therapeutics Inc31.39m-85.77m352.41m100.00--2.00--11.23-2.42-2.420.8363.510.2249--3.59341,172.60-61.46-69.86-71.67-82.6994.45---273.27-7,501.598.63--0.00---44.3347.76-25.35---24.50--
Cue Biopharma Inc2.74m-39.40m354.11m46.00--13.09--129.26-1.89-1.890.13021.180.061----59,556.52-87.76---106.17-------1,438.18------0.00-------67.77------
Cellular Biomedicine Group Inc74.97k-45.82m355.48m193.00--5.02--4,741.57-2.41-2.410.0043.480.0007--3.99388.45-43.25-49.19-50.88-52.5560.4123.64-61,113.29-3,297.70----0.1741---33.381.836.13--113.48--
OptiNose Inc26.57m-111.44m356.35m99.00--7.99--13.41-2.70-2.700.6431.070.13730.68943.77268,414.20-57.59---66.60--85.20---419.37--4.66-14.080.6252-------72.12------
Harpoon Therapeutics Inc4.61m-51.03m357.26m55.00--3.33--77.56-2.10-2.100.18994.360.0527----102,355.60-58.43---67.85-------1,108.01------0.00--570.90---62.60------
Syros Pharmaceuticals Inc2.37m-73.74m360.96m76.00--3.82--152.50-1.96-1.960.06252.230.0179----31,144.74-55.77-62.66-66.86-71.63-----3,115.38-5,476.38----0.0092--86.19---15.31--9.53--
CEL-SCI Corporation462.75k-22.13m360.99m43.00--68.83--780.09-0.6858-0.68580.01460.14570.0162--5.10---77.38-88.53-98.46-119.93-----4,783.28-5,871.522.99-7.890.7246---2.9011.8830.51--11.32--
Data as of Jan 21 2020. Currency figures normalised to Eiger BioPharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

51.68%Per cent of shares held by top holders
HolderShares% Held
Adage Capital Management LPas of 30 Sep 20192.23m9.08%
683 Capital Management LLCas of 30 Sep 20191.86m7.60%
BlackRock Fund Advisorsas of 30 Sep 20191.57m6.41%
Broadfin Capital LLCas of 30 Sep 20191.37m5.58%
Farallon Capital Management LLCas of 30 Sep 20191.13m4.59%
The Vanguard Group, Inc.as of 30 Sep 20191.07m4.35%
Ecor1 Capital LLCas of 30 Sep 20191.06m4.33%
Cormorant Asset Management LPas of 30 Sep 2019997.89k4.07%
Mangrove Partnersas of 30 Sep 2019847.28k3.46%
BVF Partners LPas of 30 Sep 2019539.51k2.20%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.